- Fujifilm’s Xair ultra-portable handheld, battery powered X-ray machine will be deployed with Qure.ai’s AI-enabled Chest X-ray solution to screen presumptive TB cases
- The partnership is aimed at augmenting active screening for TB in hotspots with the support of USAID and the Lagos State TB program.
LAGOS, Nigeria, August 12, 2022--(BUSINESS WIRE)--The Institute of Human Virology in Nigeria (IHVN) has announced their partnership with Fujifilm, the multinational medical imaging device manufacturers and Qure.ai, a global AI-enabled medical imaging solutions provider to use advanced technology to help optimize tuberculosis (TB) screening outreach in Nigeria. The partnership has enabled USAID funded IHVN to deploy ultra-portable X-ray machines embedded with AI for active case finding in Nigerian rural communities.
TB is the leading cause of death in Sub-Saharan Africa (Nigeria inclusive) and the most common opportunistic co-infection alongside HIV. Fujifilm’s Xair portable Xray device powered by the Qure.ai artificial intelligence algorithms provide an ideal solution for the rural mass testing programs, offering ultra-portability, high accuracy and efficiency point of care diagnostic solutions.
Dr. Chukwuma Anyaike, Director and National Coordinator, National Tuberculosis, Leprosy and Buruli Ulcer Control Program - Federal Ministry of Health NIGERIA, said, "The successful piloting of the use of portable digital x-ray from Fujifilm with Qure.ai technology by IHVN in collaboration with NTBLCP, Federal Ministry of Health Nigeria has proven its positive impact on case detection of tuberculosis."
Commenting on the partnership, Dr Aderonke Agbaje, Chief of Party USAID TB-LON 3 Project at Institute of Human Virology Nigeria, said, "IHVN is at the forefront of battling TB and correlated infections using innovative solutions to optimise care delivery. Through our efforts (rural dwellers in communities with difficult terrains have been reached with TB care). Our partnership with Fujifilm and Qure.ai for AI enabled TB screening is our most recent initiatives towards community outreach. We look forward to scaling active case finding efforts and improving patient care."
The United States Agency for International Development (USAID) is working with IHVN to rapidly increase the level of TB cases detected and treated in Nigeria over the next five years. The project aims to improve access to high-quality, patient-centric treatment for TB, including drug-resistant tuberculosis and co-infections with HIV, which is common in the community. The project also covers contact tracing of TB presumptive cases to curb contagion and bring more cases under the aegis of the national TB reporting system. IHVN is the implementing partner for the project that covers the states of Lagos, Osun, Ogun, and Oyo.
Commenting on the development, Godspower Asika, National Sales Manager – Nigeria, Fujifilm Middle East & Africa, said, "We are happy to note that IHVN is screening numerous communities in Nigeria with our ultra-portable x-ray machine, the Fujifilm FDR Xair, which is integrated with AI technology from Qure.ai. We applaud the Federal Ministry of Health of Nigeria's NTBLCP leadership for working kindly with IHVN to accomplish this, and Fujifilm will continue to make its technology available to all partners and stakeholders."
Fujifilm FDR Xair is a battery-powered, ultralight, and compact X-ray device that can function for hours without electricity. FDR Xair, coupled with Qure.ai’s Al-powered radiological image analysis allows for accurate screening & detection of lung abnormalities, and presumptive TB even in the remotest parts of the world and can be beneficial in expediting the process of TB diagnosis at the point of care.
Commenting on the partnership, Prashant Warier, CEO and Founder, Qure.ai said, "We are excited to partner with Fujifilm on this project to combine two state-of-the-art technologies for the greater communal good. Our AI enabled chest X-ray solution, qXR, has been evaluated by WHO and meets their criteria for TB triage and screening in the absence of a human reader. IHVN’s Nigeria project will help reinforce what superior technology can do for universal lung health and healthcare access for everyone."
Qure.ai's chest X-ray software can detect multiple lung abnormalities within a minute. It can accurately assess radiological findings suggestive of a host of diseases, including pneumonia, COPD, TB, and Heart Failure, among others.
Together IHVN, Fujifilm and Qure.ai aim to strengthen the systems and structures for tuberculosis detection, treatment, and notification in rural Nigeria. The partnership will help in reducing the transmission and progression of tuberculosis and aid in accelerating tuberculosis research and innovation to improve the quality of programs implemented.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005835/en/
Amrutha Joseph | Amrutha.joseph@qure.ai
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
As back-to-school approaches the CDC no longer recommends quarantining if exposed to the omicron virus.
In the recall expansion, “botulism” has been mentioned.
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
Joining me on the call today are Sujal Shah, chief executive officer; Chuck McWherter, chief scientific officer; Dennis Kim, chief medical officer; Lewis Stuart, chief commercial officer; and Dan Menold, VP, finance. Following our prepared remarks, we will open the call for Q&A. Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay's expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated time lines and data release date, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
The Supreme Court decision to overturn Roe v Wade triggered a wave of outrage from pro-choice groups as states moved quickly to criminalize abortion. Now, investors are taking action with their dollars, deploying capital to support women’s health startups.
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
Everything you need to know about the biggest changes to U.S. health policy since the Affordable Care Act
Though my older child is entering first grade this year, I’ve been packing her lunches for years. As other working parents can attest, many of us start packing lunch before our children can even chew. And then, depending on what school lunch is available, and whether our kids will eat it, we continue to pack lunches. Every. Single. Day.
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
The latest guidance aligns with the recommendations set for those who are up to date on their COVID-19 vaccines
The House moved Friday to pass a sweeping climate and health care bill, delivering a long-awaited legislative win to President Biden’s desk for his signature. The White House is preparing to deploy officials across the country to promote the historic action on climate change and lowering prescription drug costs contained in the bill, pitching it…
The FDA has repeatedly cited India's Aurobindo for unsafe manufacturing practices, but still lets it dominate the U.S. market for generic drugs.